Notogen Inc.

Notogen is a preclinical-stage biotechnology company focused on developing regenerative therapeutics for musculoskeletal conditions, specifically targeting degenerative disc disease (DDD). The company's approach centers on non-cellular, protein-based biologics that aim to halt the progression of spinal degeneration and induce restorative effects in the intervertebral disc. Their lead candidate, NTG-101, is a patented formulation of recombinant human growth factors (TGF-β1 and CTGF) designed for a single intradiscal injection. Notogen's technology is based on over 20 years of research into notochordal cells and their role in disc homeostasis, aiming to provide a disease-modifying alternative to invasive surgery or complex cell therapies.